latent GDF-8
latent GDF-8 Molekülinformation
| Englischer Name | Growth/differentiation factor 8 | Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 6 | Target-Alias | MSTN，GDF-8，GDF8，Growth Differentiation Factor 8，MSLHP，Myostatin，Growth/Differentiation Factor 8 |
| Höchste Forschungs- und Entwicklungsphase | NDA/BLA | ||
| Englischer Name | Growth/differentiation factor 8 |
| Target-Alias | MSTN，GDF-8，GDF8，Growth Differentiation Factor 8，MSLHP，Myostatin，Growth/Differentiation Factor 8 |
| Anzahl der inverkehr gebrachten Arzneimittel | 0 |
| Anzahl der klinischen Arzneimittel | 6 |
| Höchste Forschungs- und Entwicklungsphase | NDA/BLA |
Produktanfrage
latent GDF-8 Molekülhintergrund
Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.
latent GDF-8 Molekülalias
latent GDF-8
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Talditercept alfa | RO-7239361; BMS-986089; RG-6206; BHV-2000 | Phase 3 Clinical | Bristol-Myers Squibb Company | Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal | Details |
| RO-7204239 | GYM-329; RO-7204239; RG-6237; RG-70240 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd | Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal | Details |
| Trevogrumab | REGN-1033; REGN1033; SAR-391786; GDF8 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Myositis, Inclusion Body; Obesity; Sarcopenia | Details |
| AAV1-FS344 | AAV1-Follistatin; AAV1-FS344 | Phase 2 Clinical | Nationwide Children'S Hospital | Becker muscular dystrophy; Myositis, Inclusion Body; Muscular Dystrophy, Duchenne | Details |
| KER-065 | KER-065; RKER-065 | Phase 1 Clinical | Keros Therapeutics Inc | Neuromuscular Diseases; Obesity | Details |
| HS135 | HS-135 | Phase 1 Clinical | 35Pharma Inc | Hypertension, Pulmonary; Heart Failure, Diastolic; Pulmonary Arterial Hypertension | Details |
- Molekülinformation
- Produktanfrage
- Klinische Arzneimittelinformation